Literature DB >> 17464244

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.

Richard L Piekarz1, Dan L Sackett, Susan E Bates.   

Abstract

The histone deacetylase inhibitors are a new class of agents that are currently in various stages of clinical development. Clinical trials have demonstrated activity, urging further investigation. At the same time, it has been discovered that these agents have their own challenges. In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17464244     DOI： 10.1097/PPO.0b013e31803c73cc

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  18 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

Review 2.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

3.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

Authors:  Min-Yu Chen; Warren S-L Liao; Zhen Lu; William G Bornmann; Violeta Hennessey; Michele N Washington; Gary L Rosner; Yinhua Yu; Ahmed Ashour Ahmed; Robert C Bast
Journal:  Cancer       Date:  2011-10-01       Impact factor: 6.860

4.  Entinostat: a promising treatment option for patients with advanced breast cancer.

Authors:  Roisin M Connolly; Michelle A Rudek; Richard Piekarz
Journal:  Future Oncol       Date:  2017-03-09       Impact factor: 3.404

5.  HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells.

Authors:  Xufeng Chen; Patty Wong; Eric Radany; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

6.  Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Authors:  Robin Frye; Mary Myers; Karen C Axelrod; Elizabeth A Ness; Richard L Piekarz; Susan E Bates; Susan Booher
Journal:  Clin J Oncol Nurs       Date:  2012-04       Impact factor: 1.027

7.  Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells.

Authors:  Nong Xiang; Rui Zhao; Guoqing Song; Weixiong Zhong
Journal:  Carcinogenesis       Date:  2008-08-01       Impact factor: 4.944

8.  Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.

Authors:  Takashi Mine; Satoko Matsueda; Yufeng Li; Hiroshi Tokumitsu; Hui Gao; Cristopher Danes; Kwong-Kwok Wong; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

Review 9.  Histone deacetylase inhibitors in cancer therapy.

Authors:  Min-Jung Lee; Yeong Sang Kim; Shivaani Kummar; Giuseppe Giaccone; Jane B Trepel
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

10.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.